# EDGAR Filing Document

**Accession Number:** 0001162194
**File Stem:** 0001193125-25-264693
**Filing Date:** 2025-11
**Character Count:** 45693
**Document Hash:** b33f353e4c8da6932a6f5b6d2bb1604a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-264693.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001193125-25-264693

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251104

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STANDARD BIOTOOLS INC.
- **CENTRAL INDEX KEY:** 0001162194
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 770513190
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34180
- **FILM NUMBER:** 251449115

**BUSINESS ADDRESS:**
- **STREET 1:** 2 TOWER PLACE
- **STREET 2:** SUITE 2000
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 6502666000

**MAIL ADDRESS:**
- **STREET 1:** 2 TOWER PLACE
- **STREET 2:** SUITE 2000
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLUIDIGM CORP
- **DATE OF NAME CHANGE:** 20011113

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported):** November 4, 2025

------

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| Delaware<br>(State or other jurisdiction of <br>incorporation or organization) | 001-34180<br>(Commission File Number) | 77-0513190<br>(I.R.S. Employer Identification Number) |
| 2 Tower Place**,** Suite 2000<br>South San Francisco**,** California 94080 | 2 Tower Place**,** Suite 2000<br>South San Francisco**,** California 94080 | 2 Tower Place**,** Suite 2000<br>South San Francisco**,** California 94080 |
| (Address of principal executive offices and zip code) | (Address of principal executive offices and zip code) | (Address of principal executive offices and zip code) |
| **(**650**)** 266-6000 | **(**650**)** 266-6000 | **(**650**)** 266-6000 |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common stock, $0.001 par value per share | LAB | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 - Results of Operations and Financial Condition**

On November 4, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and nine months ended September 30, 2025. The press release is attached hereto as Exhibit 99.1.

The information set forth in the press release, except for the information set forth under the headings "Operational Restructuring," "Full Year 2025 Revenue Outlook" and "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

**Item 7.01. Regulation FD Disclosure.**

The information set forth under the headings "Operational Restructuring," "Full Year 2025 Revenue Outlook" and "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

**Item 9.01 - Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [<u>Press release issued by Standard BioTools Inc., dated November 4, 2025</u>](lab-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: | November 4, 2025 |
| **STANDARD BIOTOOLS INC.** | **STANDARD BIOTOOLS INC.** |
| By: | /s/ Alex Kim |
| Name: | Alex Kim |
| Title: | Chief Financial Officer |
|  | (Principal Financial and Accounting Officer) |

---

------

## Exhibit 99.1

**Exhibit 99.1**

![img96762296_0.jpg](img96762296_0.jpg)

**Standard BioTools Reports Third Quarter 2025 Financial Results**

SOUTH SAN FRANCISCO, Calif., November 4, 2025 -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended September 30, 2025.

**Recent Highlights:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Third quarter 2025 total combined company revenue of $46.2 million; Revenue from continuing operations of $19.6 million*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Implemented restructuring plan expected to deliver over $40 million in annualized cost savings; On track to achieve positive adjusted EBITDA target in 2026*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*$217.0 million in cash & cash equivalents as of September 30, 2025; Approximately $550 million in cash & cash equivalents expected at close of transaction with Illumina in first half of 2026 to fuel inorganic growth strategy* 

"The third quarter marked another period of solid execution as we sharpen our focus and position Standard BioTools for the next stage," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Our commercial team delivered consistent overall performance amid a still-evolving macro environment, and with cost savings initiatives beginning to take hold, we are simplifying operations, increasing productivity and driving the go-forward business toward profitability expected in 2026. Combined with a strong balance sheet at quarter end and the significant cash injection expected from the pending Illumina transaction, we are well positioned to expand our portfolio through strategic M&A that we believe will fuel growth and deliver long-term value for our shareholders."

**Operational Restructuring** 

In September, as previously disclosed in the Company's SEC filings, the Company implemented a phased operational restructuring plan expected to deliver over $40 million in total annualized cost savings, to be fully realized in 2026. The plan included an aggregate reduction-in-force of approximately 20% of its global workforce as well as initiatives designed to increase operating efficiency, reduce costs, and align resources with the Company's long-term strategic objectives. These actions reinforce the Company's path to generating positive adjusted EBITDA expected in 2026.

"Given the current operating environment, these decisions were important to keep our organization lean, focused and positioned to emerge stronger tomorrow than we are today," said Alex Kim, Chief Financial Officer of Standard BioTools. "I want to sincerely thank our departing colleagues for their contributions as we take these steps to secure the long-term success of Standard BioTools – delivering innovative solutions to our customers as they advance science and improve human health."

The cost savings initiative, together with the continued application of the Standard BioTools Business System (SBS), is expected to generate efficiencies across sales and marketing, research and development, and general and administrative functions. As previously announced, Standard BioTools will consolidate its South San Francisco operations into its Singapore facility, co-locating research and development with manufacturing. As part of this transition, the Company also plans to establish its global headquarters in Boston.

------

<br> **Financial Results Table: Continuing Operations**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| ***(Unaudited, in millions, except percentages)*** | **2025** | **2024** | **2025** | **2024** |
| Revenue | $19.6 | $22.1 | $61.5 | $66.2 |
| Gross margin | 48.5% | 54.9% | 50.6% | 50.6% |
| Non-GAAP gross margin | 53.5% | 57.3% | 54.9% | 55.2% |
| Operating expenses | $42.4 | $38.8 | $116.8 | $134.9 |
| Non-GAAP operating expenses | $27.0 | $26.3 | $80.5 | $84.5 |
| Operating loss | $(32.9) | $(26.7) | $(85.6) | $(101.4) |
| Net loss from continuing operations | $(31.7) | $(21.9) | $(72.7) | $(63.8) |
| Adjusted EBITDA | $(16.5) | $(13.7) | $(46.8) | $(48.0) |
| Cash, cash equivalents, restricted cash, short-term and long-term investments | $217.0 | $338.1 | $217.0 | $338.1 |

---

**Third Quarter 2025 Financial Results: Continuing Operations**

Following the announced sale of SomaLogic, Inc. ("SomaLogic") and other specified assets to Illumina, Inc. ("Illumina") in June 2025, all financial results in this section reflect continuing operations only.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Revenue** was $19.6 million in the third quarter of 2025, down 11% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Consumables** revenue was $8.7 million in the third quarter of 2025, down 17% year-over-year. Lower consumables revenue in the quarter reflected project funding declines in flow and microfluidics, partially offset by growth in imaging.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Instruments** revenue was $5.1 million in the third quarter of 2025, down 3% year-over-year. Instrument revenue in the quarter reflected growth in imaging but overall remained impacted by capital-constrained end-markets globally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Services** revenue, which is predominantly Field Services, was $5.8 million in the third quarter of 2025, down 9% year-over-year. Field Services revenue decreased due to fewer active service contracts and lower on-demand revenue driven by improved instrument quality and uptime.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Gross margins** in the third quarter of 2025 were approximately 48.5%, versus 54.9% in the third quarter of 2024; and non-GAAP gross margins in the third quarter of 2025 were approximately 53.5%, versus 57.3% in the third quarter of 2024. Gross margins and non-GAAP gross margins were driven by volume and product mix.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Operating expenses** in the third quarter of 2025 were $42.4 million, an increase of $3.6 million, or up 9%, compared to the third quarter of 2024. Operating expenses included $9.4 million in restructuring and related charges. Non-GAAP operating expenses, which exclude transaction costs, stock-based compensation, and restructuring charges, were $27.0 million in the third quarter of 2025, an increase of $0.7 million, or up 3%, compared to the third quarter of 2024. The increase in operating expenses is due to the reclassification of SomaLogic as discontinued operations and the retention of shared corporate costs within continuing operations, more than offsetting lower R&D expenses and continued productivity gains from SBS.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Net loss** for the third quarter of 2025 was $31.7 million, compared to a net loss of $21.9 million in the third quarter of 2024, representing an increase of $9.8 million or 45%, while adjusted EBITDA for the third quarter of 2025 was a loss of $16.5 million, versus an adjusted EBITDA loss of $13.7 million in the third quarter of 2024, an increase of $2.9 million, or 21%.

------

**Full Year 2025 Revenue Outlook**

For fiscal year 2025, the Company continues to expect combined revenue in the range of $165 million to $175 million. Revenue from continuing operations is expected to be in the range of $78 million to $83 million.

**Use of Non-GAAP Financial Information**

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company's core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company's core operating results. Management uses non-GAAP measures to compare the Company's performance relative to forecasts and strategic plans and to benchmark the Company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company's operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

**Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to future revenue and expected cash at the closing of the transaction with Illumina; operational and strategic plans, including potential cost savings from the operational restructuring plan and the timing for realizing such cost savings; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits and synergies of prior and potential future acquisitions, including the potential for such transactions to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of announced divestures and prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company's development activities and results of operation; the timing of the closing of the transaction with Illumina and the operating expenses over the intervening period; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company's plans, or both; risks that the Company's expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company's business or external market conditions; anticipated NIH funding pressures; the expected effect from U.S. export controls and the expected impact from tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company's products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company's research and development activities, and

------

distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the "Risk Factors" section of the Company's annual report on Form 10-K, for the year ended December 31, 2024, filed with the SEC on March 11, 2025, the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 15, 2025, and in the Company's other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

**About Standard BioTools Inc.**

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

**For Research Use Only. Not for use in diagnostic procedures.**

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.

Patent and License Information: standardbio.com/legal/notices. <br>Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners.©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

**Investor Contact:**

<u>ir@standardbio.com</u>

****

------

**STANDARD BIOTOOLS INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**Continuing Operations**

*(In thousands, except per share amounts)*

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product revenue | $13800 | $15779 | $44254 | $46987 |
| &nbsp;&nbsp;&nbsp;&nbsp;Services and other revenue | 5752 | 6307 | 17282 | 19244 |
| Total revenue | 19552 | 22086 | 61536 | 66231 |
| Cost of revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product revenue | 6728 | 6159 | 20767 | 21775 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of services and other revenue | 3340 | 3801 | 9608 | 10930 |
| Total cost of revenue | 10068 | 9960 | 30375 | 32705 |
| Gross profit | 9484 | 12126 | 31161 | 33526 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 6356 | 6939 | 18018 | 21791 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 26595 | 24466 | 84524 | 75740 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | 9428 | 2341 | 12707 | 12374 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transaction and integration expenses | 43 | 5079 | 1517 | 25024 |
| Total operating expenses | 42422 | 38825 | 116766 | 134929 |
| Loss from continuing operations | (32938) | (26699) | (85605) | (101403) |
| Bargain purchase gain |  |  |  | 25213 |
| Interest income | 2140 | 4794 | 7517 | 16303 |
| Interest expense | (10) | (853) | (21) | (2744) |
| Other income (expense), net | (2092) | 957 | 3438 | (865) |
| Loss from continuing operations before income taxes | (32900) | (21801) | (74671) | (63496) |
| Income tax benefit (expense) | 1216 | (118) | 1944 | (270) |
| Net loss from continuing operations | (31684) | (21919) | (72727) | (63766) |
| Discontinued operations: |  |  |  |  |
| Loss from discontinued operations, net of tax | (3003) | (5019) | (21452) | (41047) |
| Net loss | (34687) | (26938) | (94179) | (104813) |
| Induced conversion of redeemable preferred stock |  |  |  | (46014) |
| Net loss attributable to common stockholders | $(34687) | $(26938) | $(94179) | $(150827) |
| Net loss per share from continuing operations, basic and diluted | $(0.08) | $(0.06) | $(0.19) | $(0.32) |
| Net loss per share from discontinued operations, basic and diluted | $(0.01) | $(0.01) | $(0.06) | $(0.12) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.09) | $(0.07) | $(0.25) | $(0.44) |
| Shares used in computing net loss per share attributable to common stockholders, basic and diluted | 382630 | 371538 | 380468 | 346093 |

---

------

**STANDARD BIOTOOLS INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**Continuing Operations**

*(In thousands)*

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $129418 | $166728 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 65485 | 126146 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 13536 | 14741 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 25418 | 20744 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 7906 | 4561 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current assets held for sale | 230676 | 42963 |
| Total current assets | 472439 | 375883 |
| Property and equipment, net | 20738 | 22775 |
| Operating lease right-of-use asset, net | 23453 | 26567 |
| Other non-current assets | 3521 | 3688 |
| Long-term investments | 19485 |  |
| Non-current assets held for sale |  | 183432 |
| Total assets | $539636 | $612345 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $6619 | $5049 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 30810 | 21435 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, current | 5113 | 4806 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue, current | 40111 | 10274 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred grant income, current | 3098 | 3527 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current liabilities held for sale | 22214 | 20804 |
| Total current liabilities | 107965 | 65895 |
| Convertible notes, non-current | 299 | 299 |
| Deferred tax liability | 1139 | 1081 |
| Operating lease liabilities, non-current | 21977 | 25590 |
| Deferred revenue, non-current | 2366 | 32674 |
| Deferred grant income, non-current | 5031 | 7243 |
| Other non-current liabilities | 1200 | 1062 |
| Non-current liabilities held for sale |  | 6779 |
| Total liabilities | 139977 | 140623 |
| Total stockholders' equity | 399659 | 471722 |
| Total liabilities and stockholders' equity | $539636 | $612345 |

---

------

**STANDARD BIOTOOLS INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** 

*(In thousands)*

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** |
| **Operating activities** |  |  |
| Net loss | $(94179) | $(104813) |
| Bargain purchase gain |  | (25213) |
| Stock-based compensation expense | 23870 | 24262 |
| Amortization of acquired intangible assets | 1715 | 3533 |
| Depreciation and amortization | 7971 | 9375 |
| Accretion of discount on short-term investments, net | (2182) | (6303) |
| Non-cash lease expense | 4435 | 4348 |
| Provision for excess and obsolete inventory | 1975 | 1991 |
| Change in fair value of warrants | (232) | (474) |
| Change in fair value of contingent consideration | (3400) |  |
| Other non-cash items | 922 | 1111 |
| Changes in assets and liabilities, net | (14048) | (37212) |
| Net cash used in operating activities | (73153) | (129395) |
| **Investing activities** |  |  |
| Cash and restricted cash acquired in merger |  | 280033 |
| Purchases of short-term investments | (91241) | (226612) |
| Purchases of long-term investments | (19483) |  |
| Proceeds from sales and maturities of investments | 154000 | 289000 |
| Purchases of property and equipment | (7827) | (4973) |
| Net cash provided by investing activities | 35449 | 337448 |
| **Financing activities** |  |  |
| Repayment of term loan and convertible notes |  | (8192) |
| Payment of term loan fee |  | (545) |
| Repurchase of common stock |  | (40490) |
| Proceeds from ESPP stock issuance | 308 | 425 |
| Payments for taxes related to net share settlement of equity awards and other | (358) | (414) |
| Proceeds from exercise of stock options |  | 1120 |
| Net cash provided by (used in) financing activities | (50) | (48096) |
| Effect of foreign exchange rate fluctuations on cash and cash equivalents | 942 | (518) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (36812) | 159439 |
| Cash, cash equivalents and restricted cash at beginning of period | 168818 | 52499 |
| Cash, cash equivalents and restricted cash at end of period | $132006 | $211938 |
| Cash, cash equivalents, and restricted cash consists of: |  |  |
| Cash and cash equivalents | $129418 | $210647 |
| Restricted cash | 2588 | 1291 |
| Total cash, cash equivalents and restricted cash | $132006 | $211938 |

---

------

**STANDARD BIOTOOLS INC.**

**REVENUE**

**Continuing Operations**

*(In thousands)*

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Product revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Instruments | $5095 | $5271 | $16956 | $17221 |
| &nbsp;&nbsp;&nbsp;&nbsp;Consumables | 8705 | 10508 | 27298 | 29766 |
| Total product revenue | 13800 | 15779 | 44254 | 46987 |
| Services and other revenue | 5752 | 6307 | 17282 | 19244 |
| Total revenue | $19552 | $22086 | $61536 | $66231 |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Continuing Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Gross profit | $9484 | $12126 | $31161 | $33526 |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  |  |  | 1407 |
| &nbsp;&nbsp;Depreciation and amortization | 590 | 318 | 1407 | 1017 |
| &nbsp;&nbsp;Stock-based compensation expense | 386 | 218 | 1030 | 601 |
| &nbsp;&nbsp;Loss on disposal of property and equipment |  |  | 187 |  |
| &nbsp;&nbsp;Cost of sales adjustment |  |  |  |  |
| Non-GAAP gross profit | $10460 | $12662 | $33785 | $36551 |
| Gross margin percentage | 48.5% | 54.9% | 50.6% | 50.6% |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  |  |  | 2.2% |
| &nbsp;&nbsp;Depreciation and amortization | 3.0% | 1.4% | 2.3% | 1.5% |
| &nbsp;&nbsp;Stock-based compensation expense | 2.0% | 1.0% | 1.7% | 0.9% |
| &nbsp;&nbsp;Loss on disposal of property and equipment |  |  | 0.3% |  |
| &nbsp;&nbsp;Cost of sales adjustment |  |  |  |  |
| Non-GAAP gross margin percentage | 53.5% | 57.3% | 54.9% | 55.2% |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Continuing Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Operating expenses | $42422 | $38825 | $116766 | $134929 |
| &nbsp;&nbsp;Restructuring and related charges | (9428) | (2341) | (12707) | (12374) |
| &nbsp;&nbsp;Transaction and integration expenses | (43) | (5079) | (1517) | (25024) |
| &nbsp;&nbsp;Stock-based compensation expense | (4938) | (4431) | (17715) | (11026) |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  |  |  |  |
| &nbsp;&nbsp;Depreciation and amortization | (1009) | (650) | (4286) | (1945) |
| &nbsp;&nbsp;Loss on disposal of property and equipment |  | (4) |  | (27) |
| Non-GAAP operating expenses | $27004 | $26320 | $80541 | $84533 |
| R&D operating expenses | $6356 | $6939 | $18018 | $21791 |
| &nbsp;&nbsp;Stock-based compensation expense | (497) | (403) | (1317) | (1047) |
| &nbsp;&nbsp;Depreciation and amortization | (228) | (148) | (997) | (437) |
| &nbsp;&nbsp;Gain on disposal of property and equipment |  |  | 28 |  |
| Non-GAAP R&D operating expenses | $5631 | $6388 | $15732 | $20307 |
| SG&A operating expenses | $26595 | $24466 | $84524 | $75740 |
| &nbsp;&nbsp;Stock-based compensation expense | (4441) | (4028) | (16398) | (9979) |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  |  |  |  |
| &nbsp;&nbsp;Depreciation and amortization | (781) | (502) | (3289) | (1508) |
| &nbsp;&nbsp;Loss on disposal of property and equipment |  | (4) | (28) | (27) |
| Non-GAAP SG&A operating expenses | $21373 | $19932 | $64809 | $64226 |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Continuing Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net loss | $(31684) | $(21919) | $(72727) | $(63766) |
| &nbsp;&nbsp;Income tax (benefit) expense | (1216) | 118 | (1944) | 270 |
| &nbsp;&nbsp;Interest income | (2140) | (4794) | (7517) | (16303) |
| &nbsp;&nbsp;Interest expense | 10 | 853 | 21 | 2744 |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  |  |  | 1407 |
| &nbsp;&nbsp;Depreciation and amortization | 1599 | 967 | 5693 | 2961 |
| &nbsp;&nbsp;Bargain purchase gain |  |  |  | (25213) |
| &nbsp;&nbsp;Restructuring and related charges | 7216 | 2341 | 10495 | 12374 |
| &nbsp;&nbsp;Transaction and integration expenses | 43 | 5079 | 1517 | 25024 |
| &nbsp;&nbsp;Stock-based compensation expense | 7536 | 4649 | 20957 | 11627 |
| &nbsp;&nbsp;Cost of sales adjustment |  |  |  |  |
| &nbsp;&nbsp;Loss on disposal of property and equipment |  | 4 | 187 | 27 |
| &nbsp;&nbsp;Other non-operating (income) expense | 2092 | (957) | (3438) | 865 |
| Adjusted EBITDA | $(16544) | $(13658) | $(46756) | $(47982) |

---

------

**STANDARD BIOTOOLS INC.**

**Condensed Results of Operations**

**Discontinued Operations**

*(In thousands)*

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> September 30,** | **Three Months Ended<br> September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue | $26693 | $22884 | $67466 | $61484 |
| Cost of revenue | 14352 | 11749 | 37784 | 32653 |
| Selling, general and administrative expenses | 8474 | 9937 | 25573 | 43280 |
| Research and development | 4849 | 6217 | 16587 | 26567 |
| Transaction and integration expenses | 2203 | - | 12710 | - |
| Other (income) expense, net | (182) | - | (3736) | 31 |
| Total expenses | $29696 | $27903 | $88918 | $102531 |
| Loss from discontinued operations | $(3003) | $(5019) | $(21452) | $(41047) |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Discontinued Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Gross profit | $12340 | $11134 | $29682 | $28831 |
| Amortization of acquired intangible assets |  | 540 | 1370 | 1644 |
| Depreciation and amortization | (76) | 1126 | 1276 | 2418 |
| Stock-based compensation expense | 214 | 146 | 628 | 296 |
| Loss on disposal of property and equipment | 7 |  | 65 |  |
| Cost of sales adjustment |  |  |  | (1812) |
| Non-GAAP gross profit | $12485 | $12946 | $33021 | $31377 |
| Gross margin percentage | 46.2% | 48.7% | 44.0% | 46.9% |
| Amortization of acquired intangible assets |  | 2.4% | 2.0% | 2.6% |
| Depreciation and amortization | (0.2)% | 4.9% | 1.9% | 3.9% |
| Stock-based compensation expense | 0.8% | 0.6% | 0.9% | 0.5% |
| Loss on disposal of property and equipment |  |  | 0.1% |  |
| Cost of sales adjustment |  |  |  | (2.9)% |
| Non-GAAP gross margin percentage | 46.8% | 56.6% | 48.9% | 51.0% |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Discontinued Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Operating expenses | $15526 | $16154 | $54974 | $69847 |
| &nbsp;&nbsp;Restructuring and related charges |  |  | (104) |  |
| &nbsp;&nbsp;Transaction and integration expenses | (2203) |  | (12710) |  |
| &nbsp;&nbsp;Stock-based compensation expense | (724) | (1126) | (2285) | (12339) |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  | (171) | (345) | (482) |
| &nbsp;&nbsp;Depreciation and amortization |  | (1053) | (1004) | (3995) |
| &nbsp;&nbsp;Loss on disposal of property and equipment | (9) | (26) | (199) | (388) |
| Non-GAAP operating expenses | $12590 | $13778 | $38327 | $52643 |
| R&D operating expenses | $4849 | $6217 | $16587 | $26567 |
| &nbsp;&nbsp;Stock-based compensation expense | (258) | (321) | (1139) | (3433) |
| &nbsp;&nbsp;Depreciation and amortization |  | (799) | (843) | (2169) |
| &nbsp;&nbsp;Loss on disposal of property and equipment | (9) |  | (175) |  |
| Non-GAAP R&D operating expenses | $4582 | $5097 | $14430 | $20965 |
| SG&A operating expenses | $8474 | $9937 | $25573 | $43280 |
| &nbsp;&nbsp;Stock-based compensation expense | (466) | (805) | (1146) | (8906) |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  | (171) | (345) | (482) |
| &nbsp;&nbsp;Depreciation and amortization |  | (254) | (161) | (1826) |
| &nbsp;&nbsp;Loss on disposal of property and equipment |  | (26) | (24) | (388) |
| Non-GAAP SG&A operating expenses | $8008 | $8681 | $23897 | $31678 |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Discontinued Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net loss | $(3003) | $(5019) | $(21452) | $(41047) |
| &nbsp;&nbsp;Income tax (benefit) expense | (1) |  | (158) | 31 |
| &nbsp;&nbsp;Interest income |  |  |  |  |
| &nbsp;&nbsp;Interest expense |  |  |  |  |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  | 711 | 1715 | 2126 |
| &nbsp;&nbsp;Depreciation and amortization | (76) | 2180 | 2280 | 6414 |
| &nbsp;&nbsp;Bargain purchase gain |  |  |  |  |
| &nbsp;&nbsp;Restructuring and related charges |  |  | 104 |  |
| &nbsp;&nbsp;Transaction and integration expenses | 2203 |  | 12710 |  |
| &nbsp;&nbsp;Stock-based compensation expense | 938 | 1272 | 2913 | 12635 |
| &nbsp;&nbsp;Cost of sales adjustment |  |  |  | (1812) |
| &nbsp;&nbsp;Loss on disposal of property and equipment | 17 | 25 | 265 | 388 |
| &nbsp;&nbsp;Other non-operating (income) expense | (183) |  | (3683) |  |
| Adjusted EBITDA | $(105) | $(832) | $(5306) | $(21266) |

---

------

**STANDARD BIOTOOLS INC.**

**Condensed Combined Results of Operations**

**Continuing Operations and Discontinued Operations**

*(In thousands)*

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> September 30,** | **Three Months Ended<br> September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue | $46245 | $44970 | $129002 | $127715 |
| Cost of revenue | 24420 | 21709 | 68159 | 65358 |
| Selling, general and administrative expenses | 35069 | 34403 | 110097 | 119020 |
| Research and development | 11205 | 13156 | 34605 | 48358 |
| Transaction and integration expenses | 2246 | 5079 | 14227 | 25024 |
| Restructuring | 9428 | 2341 | 12707 | 12374 |
| Other (income) expense, net | (1436) | (4780) | (16614) | (37606) |
| Total expenses | $80932 | $71908 | $223181 | $232528 |
| Net loss | $(34687) | $(26938) | $(94179) | $(104813) |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Continuing Operations and Discontinued Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Gross profit | $21824 | $23260 | $60843 | $62357 |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  | 540 | 1370 | 3051 |
| &nbsp;&nbsp;Depreciation and amortization | 514 | 1444 | 2681 | 3435 |
| &nbsp;&nbsp;Stock-based compensation expense | 600 | 364 | 1658 | 897 |
| &nbsp;&nbsp;Loss on disposal of property and equipment | 7 |  | 252 |  |
| &nbsp;&nbsp;Cost of sales adjustment |  |  |  | (1812) |
| Non-GAAP gross profit | $22945 | $25608 | $66804 | $67928 |
| Gross margin percentage | 47.2% | 51.7% | 47.2% | 48.8% |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  | 1.2% | 1.1% | 2.4% |
| &nbsp;&nbsp;Depreciation and amortization | 1.1% | 3.2% | 2.1% | 2.7% |
| &nbsp;&nbsp;Stock-based compensation expense | 1.3% | 0.8% | 1.3% | 0.7% |
| &nbsp;&nbsp;Loss on disposal of property and equipment |  |  | 0.1% |  |
| &nbsp;&nbsp;Cost of sales adjustment |  |  |  | (1.4)% |
| Non-GAAP gross margin percentage | 49.6% | 56.9% | 51.8% | 53.2% |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Continuing Operations and Discontinued Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Operating expenses | $57948 | $54979 | $171740 | $204776 |
| &nbsp;&nbsp;Restructuring and related charges | (9428) | (2341) | (12811) | (12374) |
| &nbsp;&nbsp;Transaction and integration expenses | (2246) | (5079) | (14227) | (25024) |
| &nbsp;&nbsp;Stock-based compensation expense | (5662) | (5557) | (20000) | (23365) |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  | (171) | (345) | (482) |
| &nbsp;&nbsp;Depreciation and amortization | (1009) | (1703) | (5290) | (5940) |
| &nbsp;&nbsp;Loss on disposal of property and equipment | (9) | (30) | (199) | (415) |
| Non-GAAP operating expenses | $39594 | $40098 | $118868 | $137176 |
| R&D operating expenses | $11205 | $13156 | $34605 | $48358 |
| &nbsp;&nbsp;Stock-based compensation expense | (755) | (724) | (2456) | (4480) |
| &nbsp;&nbsp;Depreciation and amortization | (228) | (947) | (1840) | (2606) |
| &nbsp;&nbsp;Loss on disposal of property and equipment | (9) |  | (147) |  |
| Non-GAAP R&D operating expenses | $10213 | $11485 | $30162 | $41272 |
| SG&A operating expenses | $35069 | $34403 | $110097 | $119020 |
| &nbsp;&nbsp;Stock-based compensation expense | (4907) | (4833) | (17544) | (18885) |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  | (171) | (345) | (482) |
| &nbsp;&nbsp;Depreciation and amortization | (781) | (756) | (3450) | (3334) |
| &nbsp;&nbsp;Loss on disposal of property and equipment |  | (30) | (52) | (415) |
| Non-GAAP SG&A operating expenses | $29381 | $28613 | $88706 | $95904 |

---

------

**STANDARD BIOTOOLS INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**Continuing Operations and Discontinued Operations**

*(In thousands)*

*(Unaudited)*

**ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net loss | $(34687) | $(26938) | $(94179) | $(104813) |
| &nbsp;&nbsp;Income tax (benefit) expense | (1217) | 118 | (2102) | 301 |
| &nbsp;&nbsp;Interest income | (2140) | (4794) | (7517) | (16303) |
| &nbsp;&nbsp;Interest expense | 10 | 853 | 21 | 2744 |
| &nbsp;&nbsp;Amortization of acquired intangible assets |  | 711 | 1715 | 3533 |
| &nbsp;&nbsp;Depreciation and amortization | 1523 | 3147 | 7971 | 9375 |
| &nbsp;&nbsp;Bargain purchase gain |  |  |  | (25213) |
| &nbsp;&nbsp;Restructuring and related charges | 7216 | 2341 | 10599 | 12374 |
| &nbsp;&nbsp;Transaction and integration expenses | 2246 | 5079 | 14227 | 25024 |
| &nbsp;&nbsp;Stock-based compensation expense | 8474 | 5921 | 23870 | 24262 |
| &nbsp;&nbsp;Cost of sales adjustment |  |  |  | (1812) |
| &nbsp;&nbsp;Loss on disposal of property and equipment | 17 | 29 | 452 | 415 |
| &nbsp;&nbsp;Other non-operating (income) expense | 1909 | (957) | (7121) | 865 |
| Adjusted EBITDA | $(16649) | $(14490) | $(52064) | $(69248) |

---

------